U090 Practical Considerations for Systemic Treatment of Atopic Dermatitis in Adults
DESCRIPTION
The therapeutic armamentarium for moderate-to-severe atopic dermatitis is expanding. Conventional immunomodulators (methotrexate, cyclosporine), biologics (dupilumab, tralokinumab, lebrikizumab, nemolizumab), and JAK inhibitors (abrocitinib, upadacitinib) are available, with more on the way. These exciting developments will improve patients’ quality of life, but make shared decision-making more complex. In this session, we will review practical aspects of systemic treatments for adult atopic dermatitis, including the latest relative efficacy evidence. We will discuss common and rare adverse events associated with these medications and how to monitor for and manage them. We will discuss patient characteristics that can guide which medication to choose for individual patients.
LEARNING OBJECTIVES
Compare the relative efficacy and safety of available systemic treatment options for adult atopic dermatitis, including conventional immunomodulators, biologics and JAK inhibitors.
Recognize adverse events associated with systemic treatments for atopic dermatitis and how to monitor for and manage them.
Differentiate the advantages and disadvantages of available systemic treatment options for atopic dermatitis in special populations of adults, including older adults and adults with comorbidities.
SCHEDULE
7:30 AM
Comparative efficacy of systemic treatments for atopic dermatitis in adults
Aaron Mark Drucker, MD, FAAD
7:45 AM
Using systemic treatments for atopic dermatitis safely – monitoring and recognizing adverse events
Eric Lawrence Simpson, MD, FAAD
8:00 AM
Considerations when using systemic treatments in special populations of adults with atopic dermatitis
Katrina Abuabara, MD, FAAD
8:15 AM
Question and answer time
DIRECTOR
Aaron Mark Drucker, MD, FAAD
SPEAKERS
Katrina Abuabara, MD, FAAD
Eric Lawrence Simpson, MD, FAAD
DISCLOSURES
Katrina Abuabara, MD, FAAD
Amgen – Consultant (1099 relationship)(Fees); Apogee Therapeutics – Consultant (1099 relationship)(Fees); Astria Therapeutics – Consultant (1099 relationship)(Fees); Cedar Healthcare – Stockholder(Stock); Cosmetique – Investigator(Grants/Research Funding); Healthpilot – Stockholder(Stock Options); Incyte – Consultant (1099 relationship)(Fees); Medidata – Consultant (1099 relationship)(Fees); Nektar Therapeutics – Consultant (1099 relationship)(Fees); Pfizer Inc. – Investigator(Grants/Research Funding); Picwell Inc. – Board of Directors(Stock); Sanofi – Consultant (1099 relationship)(Fees); TARGET Pharma – Advisory Board(Fees);
Aaron Mark Drucker, MD, FAAD
No financial relationships exist with ineligible companies.
Eric Lawrence Simpson, MD, FAAD
AbbVie – Consultant(Fees), Investigator(Grants/Research Funding); Aclaris Therapeutics Inc. – Consultant (1099 relationship)(Fees); Acrotech Biopharma Inc – Investigator(Grants/Research Funding); Amgen – Consultant(Fees), Investigator(Grants/Research Funding); Arcutis Biotherapeutics – Consultant(Fees); Arcutis, Inc. – Investigator(Grants/Research Funding); ASLAN – Investigator(Grants/Research Funding); Astria Therapeutics – Consultant (1099 relationship)(Fees); Attovia Therapeutics, Inc – Consultant (1099 relationship)(Fees); Bambusa Therapeutics Inc – Consultant (1099 relationship)(Fees); Castle Biosciences – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); CorEvitas – Consultant(Fees), Investigator(Grants/Research Funding); Demira – Consultant(Fees); Dermavant – Investigator(Grants/Research Funding); Dermira – Investigator(Grants/Research Funding); Eli Lilly and Company – Consultant(Fees), Investigator(Grants/Research Funding); Evomunne – Consultant (1099 relationship)(Fees); FIDE – Speaker/Faculty Education(Fees); Genentech, Inc. – Consultant (1099 relationship)(Fees); Impetus Healthcare – Consultant (1099 relationship)(Fees); Incyte Corporation – Consultant(Fees), Investigator(Grants/Research Funding); Inmagene Biopharmaceuticals – Consultant (1099 relationship)(Fees); Innovaderm Research Inc. – Consultant (1099 relationship)(Fees); Janssen Pharmaceuticals, Inc – Consultant (1099 relationship)(Fees); Kymera Therapeutics – Consultant (1099 relationship)(Fees); La Fonderie Ressources – Consultant (1099 relationship)(Fees); Leo Pharma Inc. – Consultant(Fees); National Jewish Health – Investigator(Grants/Research Funding); NUMAB Therapeutics AG – Consultant (1099 relationship)(Fees); Pfizer Inc. – Consultant(Fees), Investigator(Grants/Research Funding); Recludix Pharma – Consultant (1099 relationship)(Fees); Regeneron – Consultant(Fees), Investigator(Grants/Research Funding); Roche Products Ltd – Consultant (1099 relationship)(Fees); Sanofi – Investigator(Grants/Research Funding); Sanofi Genzyme – Consultant(Fees), Investigator(Grants/Research Funding); SITRYX – Consultant (1099 relationship)(Fees); Target RWE – Investigator(Grants/Research Funding); Veriskin – Investigator(Grants/Research Funding);